Edition:
United Kingdom

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

744.00DKK
11 Dec 2017
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
kr.744.00
Open
kr.745.00
Day's High
kr.745.00
Day's Low
kr.737.00
Volume
16,779
Avg. Vol
16,210
52-wk High
kr.1,133.00
52-wk Low
kr.681.00

Chart for

About

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The... (more)

Overall

Beta: 0.70
Market Cap(Mil.): kr.9,704.81
Shares Outstanding(Mil.): 9.21
Dividend: 5.00
Yield (%): 0.47

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-ALK-Abello Provides Pricing In New Share Issue

* PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S

07 Dec 2017

BRIEF-Alk-Abelló to issue shares in private placement

* ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

06 Dec 2017

Denmark's Alk Abello suspends dividend to support North America investment

Danish pharma company Alk Abello said on Monday it would invest 1 billion Danish crowns (118 million pounds) in its North America business, a move that is expected put a lid on earnings and revenue growth in the near term.

04 Dec 2017

Denmark's Alk Abello suspends dividend to support North America investment

Danish pharma company Alk Abello said on Monday it would invest 1 billion Danish crowns ($159 million) in its North America business, a move that is expected put a lid on earnings and revenue growth in the near term.

04 Dec 2017

UPDATE 1-Denmark's Alk Abello suspends dividend to support North America investment

Dec 4 Danish pharma company Alk Abello said on Monday it would invest 1 billion Danish crowns ($159 million) in its North America business, a move that is expected put a lid on earnings and revenue growth in the near term.

04 Dec 2017

Danish pharma company Alk Abello to invest 1 bln crowns in North America

Dec 4 Danish pharma company Alk Abello said on Monday it would invest about 1 billion Danish crowns ($159.5 million) over the next three years to develop its North America business and said it expected earnings to be subdued during this period.

04 Dec 2017

BRIEF-ALK-Abello To Invest Around DKK 1 Bln In North America​

* ‍WILL INVEST APPROXIMATELY DKK 1 BILLION TO SUCCEED IN NORTH AMERICA​

04 Dec 2017

BRIEF-ALK Reaches Agreement With Health Authorities In France

* ALK SECURES PRICING AND REIMBURSEMENT FOR ACARIZAX® IN FRANCE

30 Nov 2017

BRIEF-Alk-Abello Q3 EBITDA falls to DKK 36 million

* Q3 TOTAL REVENUE DKK ‍667​ MILLION VERSUS DKK 630 MILLION YEAR AGO

10 Nov 2017

BRIEF-Alk appoints new CFO

* ‍HE IS EXPECTED TO TAKE UP HIS NEW ROLE BY 2 JANUARY 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Nov 2017

Earnings vs. Estimates